A new derivative of the neuropeptide nociceptin (NC) has recently been developed. This molecule, the pseudopeptide [PhelY(CI-I2NH)Gly2]- nociceptin( I-13)-NHZ was found to antagonize NC inhibitory effects in peripheral smooth muscle preparations in vitro. However, contrasting results have appeared as regards its pharmacodynamic profile in the CNS. Here, we investigated the pseudopeptide effects, in vivo, on nociceptive responses in the rat. IphelY(CH2- NH)Gly2]-nociceptin( 1 - 13)~NH2 was administered intracerebroventricularly (icv.) or intrathecally (i.t.) (alone or in combination with NC), and tail-flick latencies (TFL) to radiant heat were assessed. I.c.v. [PhelY(CHzNH)Gly2]- nociceptin( l-13)-NH2 (I-10 nmoYrat) caused a short-lasting decrease (5 min) of TFL and did not antagonize the threshold lowering effect of i.c.v. NC (1 nmol/rat). At the spinal level, the i.t. administration (0.2-10 nmol/rat) of [PhelY(CH2- NH)Gly2]-nociceptin( 1 - 13)~NH2 produced a dose-dependent and long-lasting antinociceptive effect that was not modified by the administration of a high dose (30 nmol/rat i.t.) of the opioid antagonist naloxone. The i.t. co-administration of the pseudopeptide (10 nmol/rat) did not block the antinociceptive effect of i.t. NC (10 nmol/rat). These data indicate that the pseudopeptide behaves as an NC agonist at supraspinal and spinal levels in the rat tail-flick test of nociception. These different profiles in the periphery and the CNS could suggest differences between central and peripheral NC receptor/s and provide a basis for further development of antagonist molecules suitable for their characterization.
Supraspinal and spinal effects of [Phe(1)psi(CH2-NH)Gly(2)]-nociceptin(1-13)-NH2 on nociception in the rat
GUERRINI, Remo;CALO', Girolamo;
2000
Abstract
A new derivative of the neuropeptide nociceptin (NC) has recently been developed. This molecule, the pseudopeptide [PhelY(CI-I2NH)Gly2]- nociceptin( I-13)-NHZ was found to antagonize NC inhibitory effects in peripheral smooth muscle preparations in vitro. However, contrasting results have appeared as regards its pharmacodynamic profile in the CNS. Here, we investigated the pseudopeptide effects, in vivo, on nociceptive responses in the rat. IphelY(CH2- NH)Gly2]-nociceptin( 1 - 13)~NH2 was administered intracerebroventricularly (icv.) or intrathecally (i.t.) (alone or in combination with NC), and tail-flick latencies (TFL) to radiant heat were assessed. I.c.v. [PhelY(CHzNH)Gly2]- nociceptin( l-13)-NH2 (I-10 nmoYrat) caused a short-lasting decrease (5 min) of TFL and did not antagonize the threshold lowering effect of i.c.v. NC (1 nmol/rat). At the spinal level, the i.t. administration (0.2-10 nmol/rat) of [PhelY(CH2- NH)Gly2]-nociceptin( 1 - 13)~NH2 produced a dose-dependent and long-lasting antinociceptive effect that was not modified by the administration of a high dose (30 nmol/rat i.t.) of the opioid antagonist naloxone. The i.t. co-administration of the pseudopeptide (10 nmol/rat) did not block the antinociceptive effect of i.t. NC (10 nmol/rat). These data indicate that the pseudopeptide behaves as an NC agonist at supraspinal and spinal levels in the rat tail-flick test of nociception. These different profiles in the periphery and the CNS could suggest differences between central and peripheral NC receptor/s and provide a basis for further development of antagonist molecules suitable for their characterization.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
